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Short Communication
Ascorbate and Dehydroascorbic Acid as Reliable Biomarkers
of Oxidative Stress: Analytical Reproducibility and
Long-term Stability of Plasma Samples Subjected
to Acidic Deproteinization
Jens Lykkesfeldt
Section of Biomedicine, Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Copenhagen, Denmark
Abstract
Lack of post-sampling stability of ascorbate and dehy-
droascorbic acid and failure to block their in vivo equi-
librium have lowered their value as biomarkers of oxi-
dative stress and limited the ability to further investigate
their possible role in disease prevention. In the present
article, analytic reproducibility was tested by repeated
analysis of plasma aliquots from one individual over 4
years. The plasma was subjected to acidic deproteiniza-
tion with an equal volume of 10% meta-phosphoric acid
containing 2mmol/L of EDTA and analyzed for ascorbate
and dehydroascorbic acid by high-performance liquid
chromatography with coulometric detection. In a parallel
experiment, the stability of human plasma samples
treated as above and stored at 80C for 5 years was
tested in a cohort of 131 individuals. No degradation or
shift in the equilibrium between ascorbate and dehydro-
ascorbic acid was observed in either of the experiments.
In conclusion, ascorbate and dehydroascorbic acid could
be adequately preserved in plasma stored at 80C
following acidic deproteinization with meta-phosphoric
acid containing 2 mmol/L of EDTA. (Cancer Epidemiol
Biomarkers Prev 2007;16(11):2513–6)
Introduction
Ascorbate and dehydroascorbic acid (DHA) have been
used as biomarkers of oxidative stress for several years
(1). Ascorbate acts as a major radical scavenger in vivo
as well as in regenerating other antioxidants (2). Vitamin
C exists predominantly in its reduced state in vivo and
upon oxidation via the semidehydroascorbyl radical, the
resulting DHA is transported into, e.g., erythrocytes
and subsequently regenerated intracellularly to ascorbate
by one of several possible mechanisms (3). Being placed
low in the antioxidant hierarchy (4), ascorbate is con-
sidered a biomarker of oxidative stress and offers a gen-
eral indication of the antioxidant status of an individual.
Increased DHA, on the other hand, more specifically sug-
gests a redox imbalance and inadequate recycling
capacity (5-7). However, although a considerable body
of epidemiologic literature suggests an inverse correla-
tion between plasma ascorbate and the risk of develop-
ing cancer and cardiovascular disease, controlled trials
have thus far been unsuccessful in showing the health
benefits of vitamin C supplementation (1). More recently
though, ascorbate is being reexamined for its possible
antitumorigenic activity following i.v. infusion (8, 9).
Accurate and reproducible analyses of ascorbate and
DHA are necessary prerequisites for their application
as biomarkers of oxidative stress as well as understand-
ing their possible roles in disease prevention in general.
However, proper quantification of ascorbate and DHA
in biological samples poses a significant challenge in
analytic clinical chemistry. This is partly due to the labile
nature of the compounds as well as the fact that they are
in chemical and biological equilibrium with each other.
In other words, ascorbate is rapidly oxidized to DHA
ex vivo if steps are not taken to prevent this reac-
tion (10). In the older literature on ascorbate, these issues
were rarely taken into account and this often led to
inconsistent and misleading conclusions. In recent years,
the stability of the analytes and efficient blocking of their
in vivo equilibrium has become increasingly recognized
as important variables on par with traditional analytic
virtues such as specificity, sensitivity, and the absence
of interfering compounds. Unfortunately, articles are still
published in which sample handling, storage, and anal-
ysis has not been properly controlled, suggesting that a
continued emphasis on these matters is needed.
One important criterion for a biomarker in general is
that the sample from which it is measured should be
stable upon storage (11). This is of particular importance
in large clinical studies where the collection and analysis
of samples takes place over time. For vitamin C analysis,
the relevance of this aspect is further emphasized by the
lability of the compound. Another significant problem
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with regard to the determination of DHA is that no
sensitive, direct, and specific assay for DHA is currently
available. Consequently, DHA is usually calculated by
subtraction of the ascorbate concentration from that of
total ascorbate (ascorbate + DHA) measured after reduc-
tion (12). Although this concept remains the best avail-
able, it amplifies the requirement for accurate measure-
ment. Consequently, considerable effort has been put
into developing and testing various storage conditions
and their effect on stability. In particular, Margolis and
coworkers have consistently pursued the improvement
of reproducibility in vitamin C analyses within and be-
tween laboratories (13-16). Most work has focused on the
general and less critical measurement of vitamin C or
ascorbate, but a few studies have also investigated the
combined measurement of ascorbate and DHA and
found almost complete preservation of total ascorbate
(preserved with reductant) for up to 6 years, but not
of ascorbate, suggesting that the in vivo equilibrium
between ascorbate and DHA was not successfully
blocked (14, 15, 17).
The most commonly used method of stabilizing
biological samples for vitamin C analysis is by acidic
deproteinization with meta-phosphoric acid (MPA; refs.
10, 14, 15, 18). We also include EDTA in our sample
preparation solution to chelate divalent metal ions which
would otherwise promote oxidation of ascorbate to DHA
(19). We have previously reported that no significant
changes in ascorbate and DHA concentrations could be
observed following up to 2 months of storage (10). In the
present article, data from two experiments are reported:
the reproducibility of ascorbate and total ascorbate
measurements in plasma aliquots subjected to repeated
analysis over 4 years, and the stability of plasma ascor-
bate and DHA in a cohort of 131 individuals after 5 years
of storage.
Materials and Methods
Experiment I. Venous blood was drawn from one
apparently healthy volunteer with a butterfly needle
(21-gauge) carefully avoiding hemolysis. Following
centrifugation for 5 min at 2,000  g , the plasma was
acidified with an equal volume of 10% (w/v) MPA
containing 2 mmol/L of disodium-EDTA. The precipitate
was removed by centrifugation (5 min, 2,000  g) and
the supernatant was stored in 60 aliquots in 0.5 mL
microcentrifuge tubes at 80jC until analysis. Ascorbate
and total ascorbate were quantified as described pre-
viously (20). Briefly, ascorbate, and subsequently, total
ascorbate following reduction with tris(2-carboxyethyl)-
phosphine hydrochloride were quantified by high-
performance liquid chromatography with coulometric
detection. DHA was calculated by subtraction. Analysis
was carried out in triplicate at 20 different time points
over 4 years, i.e., a total of 60 aliquots were analyzed.
Experiment II. Individual blood samples from a
cohort of 131 apparently healthy volunteers (21, 22) were
obtained and analyzed as described above. After 5 years,
the samples were reanalyzed essentially as described in
ref. 20, except for the use of an Onyx Monolithic C18
column (100  4.6 mm i.d.; Phenomenex) at a flow rate of
1.6 mL/min resulting in a retention time of ascorbate of
f1.3 min. DHA was calculated by subtraction using uric
acid as an internal standard (20).
Statistical evaluation (Statistica v. 7.0, StatSoft) of the
data was done following Kolmogorov-Smirnov and
Lilliefors tests of normality of the distribution pattern.
Experiment I was analyzed using linear regression.
Experiment II was analyzed by using paired parametric
statistics. A P < 0.05 was considered significant.
Results
Analytic reproducibility was tested by repeated analysis
of aliquots of stabilized plasma obtained from one
individual. The results from experiment I are shown in
Fig. 1 and Table 1. Within-day coefficients of variation
averaged 1.3% and 1.7% for ascorbate and total ascor-
bate, respectively. Between-day values were 3.3% and
4.1%, respectively, including all data (Table 1). Linear
regression analysis showed no significant change in
ascorbate or total ascorbate over the course of the 4-year
study period.
The stability of plasma samples subjected to acidic
deproteinization was further evaluated by reanalyzing a
set of samples from a cohort of 131 volunteers. Plasma
ascorbate was normally distributed within the cohort
(data not shown) and the results of the analyses are
presented in Table 2. Overall, very small differences
were observed between study start and 5 years later. No
statistical differences were observed between ascorbate
and DHA measurements at study start and after 5 years,
whereas a significant 1.4% increase was observed for
total ascorbate (Table 2). Dividing the cohort into quar-
tiles showed no correlation between initial ascorbate
Figure 1. Quantification of ascorbate and total ascorbate
(following reduction) in plasma aliquots stabilized with an
equal volume of 10% of MPA containing 2% EDTA. The
samples were stored at 80jC for up to 48 mo. No significant
effect of storage time was observed on ascorbate (.) or total
ascorbate (o). Points, mean from three individual aliquots of
the parent sample; bars, SD (absence of error bars indicates that
they are smaller than the dot size). Inset, the data were normally
distributed as tested by the Kolmogorov-Smirnov and Lilliefors
tests of normality.
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level and 5-year change (Table 2). A significant inverse
correlation between initial DHA concentration and
5-year change was observed (P < 0.001).
Discussion
Four years of repeated analyses of ascorbate and total
ascorbate in aliquots of stabilized plasma confirmed the
robustness of the sample preparation and analytic
method. Overall, no significant change in either measure
over the 4-year study period was observed (Table 1).
Previously, Comstock et al. examined the stability
of ascorbate in MPA-acidified plasma samples for a
period of up to 42 months and found no indications of
‘‘important’’ loss of ascorbate during storage (23). Mar-
golis and Duewer also studied the stability of ascorbate
in MPA-acidified plasma in a particularly well-controlled
setup with several participating laboratories (15). In
MPA-treated samples stored at 70jC for up to 6 years,
ascorbate measurements declined an average of 5.5%
per year, whereas total ascorbate declined only 1% per
year suggesting that the in vivo equilibrium between
ascorbate and DHA was not entirely blocked. Inclusion
of the reductant dithiotreitol lowered the degradation to
<1% per year but also rendered the determination of
DHA impossible (15).
Koshiishi and coworkers evaluated the stability of
ascorbate following acidic deproteinization of plasma
from five individuals without storage (24). They found
that acidic deproteinization by means of trichloroa-
cetic acid and perchloric acid promoted the oxidation
of ascorbate to DHA, whereas MPA—albeit considerably
better than the former—was unable to prevent autoox-
idation. In contrast to the abovementioned data, the
authors concluded that acidic deproteinization is an
unsuitable pretreatment of plasma samples intended for
ascorbate and DHA analysis (24). However, practical
and logistic reasons necessitate that plasma samples are
stabilized for short-term, and in particular, long-term
storage in large clinical studies. Besides, although it may
indeed be practically impossible to avoid marginal post-
sampling oxidation of ascorbate, meticulous practice
and optimization could substantially lower this phenom-
enon to 1% to 2% of the total ascorbate (5, 6), which is
very far from the 15% to 20% obtained on average in the
five samples analyzed by Koshiishi et al. (24). Moreover,
our inclusion of 2 mmol/L of EDTA in the sample pre-
paration mixture might also have contributed to the
much lower post-sampling oxidation in the present
study. Thus, Buettner and Jurkiewicz have shown that
catalytic ions are the major reason for the autooxidation
of ascorbate in solution (25).
We included EDTA in the sample preparation solution
to chelate divalent metal ions which have otherwise been
shown to promote oxidation of ascorbate to DHA (19).
In the present study, changes in ascorbate and total
ascorbate amounted to 0.4% and 0.3% per year, respec-
tively (Table 2). The small increases in ascorbate and total
ascorbate between the two measurements are most likely
related to small differences between the standard curves
as they are well within the calculated between-day varia-
tion (Table 1).
On average, DHA did not change over the study
period, suggesting that the in vivo equilibrium between
ascorbate and DHA is well maintained during storage
under the conditions applied. Inclusion of an internal
standard in the reanalysis of the cohort samples gave rise
to a more narrow distribution pattern for DHA com-
pared with the original analysis (Table 2). In the biolo-
gical sense, negative concentrations have of course no
meaning; however, it should be appreciated that DHA is
measured as a difference between total ascorbate and
ascorbate (6). The concentrations of total ascorbate and
Table 1. Reproducibility of ascorbate and total ascor-
bate analysis
Ascorbate Total ascorbate
Concentration (Amol/L)
Study start 55.7 F 0.8 56.7 F 0.3
After 48 mo 56.3 F 0.1 59.9 F 1.1
Average 55.6 F 1.8 57.7 F 2.4
%CV (within-day) 1.3 1.7
%CV (between-day) 3.3 4.1
L.R. slope 0.034 0.020
L.R. intercept 56.2 58.3
Rate of change (%/y) 0.7 0.4
NOTE: Twenty aliquots were analyzed in triplicate over a period of
4 y. The ascorbate and total ascorbate concentrations did not change
significantly over the 4-year period.
Table 2. Five-year stability of ascorbate and DHA stored at 80C following acidic deproteinization
Ascorbate DHA Total ascorbate
Plasma concentration (Amol/L)
Study start (n = 133) 51.9 F 21.9 4.0 F 4.7 55.9 F 22.4
Range 4.7-111.1 21.4-25.8 5.3-126.2
95% Confidence intervals 48.1-55.7 3.2-4.8 52.0-59.7
Reanalysis after 60 mo 52.9 F 22.6 3.9 F 3.0 56.7 F 23.5*
Range 3.9-123.1 0.1-19.0 5.1-129.8
95% Confidence intervals 49.0-56.8 3.3-4.4 52.7-60.8
Change 0.98 F 5.9 0.10 F 5.3 0.88 F 4.5
Rate of change (%/y) 0.4 0.5 0.3
Change by quartiles (Amol/L)
Q1 (n = 33) 1.4 F 4.6 4.0 F 5.1
c 0.6 F 1.8
Q2 (n = 33) 2.0 F 6.1 1.6 F 3.6 1.3 F 5.1
Q3 (n = 33) 0.1 F 6.3 0.5 F 2.4 0.9 F 5.3
Q4 (n = 32) 0.3 F 6.4 5.6 F 4.6 1.9 F 5.4
*P < 0.05 compared with study start by paired t test.
cA significant inverse correlation between DHA concentration and change in DHA concentration over 5 y was found (slope, 0.995; P < 0.001).
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ascorbate are of the same magnitude and are much larger
than their difference, which amounts to a relatively small
percentage. Thus, if the DHA concentration is close to
zero, the variability of the measurement will result in a
normal distribution pattern with a considerable number
of negative observations. The original analysis encom-
passed a relatively larger error and therefore some
grossly negative (and positive) observations probably
due to pipetting error. Inclusion of uric acid as an in-
ternal standard resulted in a narrower range of DHA
concentrations and no negative values in spite of the
same average concentration (Table 2). The few very large
negative and positive DHA concentrations found at
study start resulted in changes of the same magnitude
but with opposite signs because of the reanalysis being
closer to the mean. This gave rise to a significant inverse
correlation between the original DHA concentrations and
the change over 5 years (slope 0.955; P < 0.001; Table 2).
Moreover, no correlation between the initial ascorbate
concentration and DHA change was observed, support-
ing the fact that the phenomenon indeed originates from
the narrower data distribution of DHA found at reanal-
ysis. The fact that the same average concentration was
obtained at reanalysis validates the original results but
clearly suggests that the internal standard provides a far
more precise estimate of the DHA concentration. Based
on these data, the use of internal standards in DHA
measurement is highly recommended.
In conclusion, the stabilization of plasma samples
intended for vitamin C analysis prior to storage is neces-
sary in order to block the in vivo equilibrium between
ascorbate and DHA and to prevent the degradation of
the analytes. The results of the present study show that
ascorbate and DHA could be adequately preserved in
plasma stored at 80jC following acidic deproteiniza-
tion for a period of at least 5 years.
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